Dimensional Fund Advisors Boosts Amgen Holdings

Institutional investor increases stake in biotech giant by 5.1% in Q3 2025

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Dimensional Fund Advisors LP, a major institutional investor, increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.1% in the third quarter of 2025, according to a recent SEC filing. The fund now owns 3,178,590 shares of the medical research company's stock, valued at approximately $896.8 million.

Why it matters

Amgen is one of the world's largest biotechnology companies, known for its innovative therapies in areas like oncology, nephrology, and cardiovascular disease. Dimensional Fund Advisors' increased stake signals confidence in Amgen's long-term growth potential and the company's ability to continue delivering value for shareholders.

The details

In its 13F filing with the SEC, Dimensional Fund Advisors reported acquiring an additional 154,664 shares of Amgen during the third quarter. This brings the firm's total position in Amgen to approximately 0.59% of the company's outstanding shares. The increased investment comes as Amgen has seen its stock price rise steadily over the past year, reaching a 52-week high of $391.29 in late 2025.

  • Dimensional Fund Advisors reported the increased Amgen holdings in its Q3 2025 13F filing.
  • Amgen's stock price reached a 52-week high of $391.29 in late 2025.

The players

Dimensional Fund Advisors LP

A global investment management firm that focuses on factor-based investing strategies.

Amgen Inc.

A leading global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Amgen's innovative therapies and strong market position continue to make it an attractive long-term investment for our portfolio.”

— David Booth, Co-CEO, Dimensional Fund Advisors (Marketbeat)

What’s next

Amgen is expected to report its Q4 2025 earnings in late January or early February 2026, which will provide further insight into the company's financial performance and growth outlook.

The takeaway

Dimensional Fund Advisors' increased stake in Amgen underscores the biotech giant's status as a core holding for major institutional investors. As Amgen continues to advance its pipeline and navigate industry dynamics, its ability to deliver consistent returns will be closely watched by the investment community.